Accuracies of Serum and Fecal S100 Proteins (Calprotectin and Calgranulin C) to Predict the Response to TNF Antagonists in Patients with Crohnʼs Disease

Boschetti, Gilles; Garnero, Patrick; Moussata, Driffa; Cuerq, Charlotte; Preaudat, Corinne; Duclaux-Loras, Rémi; Mialon, A.; Drai, Jocelyne; Flourié, Bernard; Nancey, Stéphane

doi:10.1097/mib.0000000000000273

Cited by 75 publications

(71 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study, one patient was excluded due to a diagnosis of IBD, but none of the other participants underwent ileocolonoscopy because of a lack of clinical symptoms. Although the increased CRP and serum calprotectin appear to be predictive markers for intestinal involvement in SpA [41] and faecal calprotectin is a well-known marker of IBD activity [54], there is no correlation between serum and faecal calprotectin [41, 55]. A beneficial effect of mild exercise on the course of IBD has been suggested [56], but the relationship between intestinal inflammation and axSpA disease activity and progression in respect to physical activity requires further research.…”

Section: Discussionmentioning

confidence: 99%

Clinical improvement and reduction in serum calprotectin levels after an intensive exercise programme for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis

et al. 2016

View full text Add to dashboard Cite

BackgroundThe efficacy of exercise therapy for ankylosing spondylitis (AS) is well-documented, but dearth of information is for non-radiographic axial spondyloarthritis (nr-axSpA).Biomarkers like serum calprotectin, interleukins IL-6, IL-17 and tumour necrosis factor (TNF)-α may reflect the disease activity of axial spondyloarthritis (axSpA). In this study, we investigated clinical and laboratory parameters of both axSpA subgroups in response to intensive physical exercise.MethodsAltogether, 46 patients with axSpA, characterised according to the Assessment of SpondyloArthritis International Society criteria as having nr-axSpA or AS underwent 6-month exercise programme. Clinical outcomes of disease activity, Bath AS Disease Activity Index (BASDAI), AS Disease Activity Index (ASDAS-CRP), mobility, Bath AS Metrology Index (BASMI) and function, Bath AS Functional Index (BASFI) were evaluated at baseline and at the end of the exercise programme. Serum IL-6 and IL-17, TNF-α and calprotectin were measured via ELISA. The clinical and laboratory data of 29 control axSpA patients were used for the evaluation of the results.ResultsIn all axSpA patients, the ASDAS-CRP (2.10 ± 0.12 to 1.84 ± 0.11, p <0.01) and BASMI (1.28 ± 0.14 to 0.66 ± 0.84, p <0.0001) improved after 6 months of exercise therapy. There was a significant improvement in the ASDAS-CRP in the nr-axSpA subgroup (2.01 ± 0.19 to 1.73 ± 0.16, p <0.05) and in the BASMI in both, the nr-axSpA and the AS subgroups (1.09 ± 0.12 to 0.47 ± 0.08, p <0.0001 and 1.43 ± 0.24 to 0.82 ± 0.23, p <0.0001, respectively). Both, ASDAS-CRP and BASDAI, were significantly improved in the exercise axSpA group compared to the control axSpA group (mean -0.26 vs. -0.13 and -0.49 vs. 0.12, respectively, all p <0.05). Only calprotectin was significantly reduced after the exercise programme in nr-axSpA and AS patients (from 2379.0 ± 243.20 to 1779.0 ± 138.30 μg/mL and from 2430.0 ± 269.70 to 1816.0 ± 148.20 μg/mL, respectively, all p <0.01). The change in calprotectin was more profound in the axSpA intervention group (mean -604.56) than in the control axSpA (mean -149.28, p <0.05).ConclusionThis study demonstrated similar efficacy for an intensive exercise programme in both nr-axSpA and AS patients. A significant decrease in serum calprotectin levels in both subgroups of axSpA patients after the exercise programme reflected an improvement in the disease activity and spinal mobility.Electronic supplementary materialThe online version of this article (doi:10.1186/s13075-016-1180-1) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical improvement and reduction in serum calprotectin levels after an intensive exercise programme for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis

et al. 2016

View full text Add to dashboard Cite

show abstract

“…High FC at baseline have been associated with increased risk of disease relapse among patients with CD, 24 while FC levels that normalize after induction therapy have been associated with sustained clinical remission among patients with CD and UC. 133,134 Lower FC levels have been associated with response to biologic therapy and clinical outcomes including clinical remission and mucosal healing. 135,136 Perhaps most useful, among patients in remission, FC has been reported to increase earlier and remain elevated prior to clinical or endoscopic relapse of disease, 137 which may indicate a role for prospective or routine monitoring with FC to identify those patients at greatest risk of relapse.…”

Section: Future Directions For Biomarkersmentioning

confidence: 99%

New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes

Barnes

Burakoff²

2016

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

Despite advances in our understanding of the pathophysiology underlying Inflammatory Bowel Disease (IBD), there remains a significant need for biomarkers that can differentiate between Crohn's Disease (CD) and Ulcerative Colitis (UC) with high sensitivity and specificity, in a cost-efficient manner. As the focus on personalized approaches to the delivery of medical treatment increases, new biomarkers are being developed to predict an individual's response to therapy as well as their overall disease course. In this review, we will outline many of the existing and recently developed biomarkers, detailing their role in the assessment of patients with IBD. We will identify opportunities for improvement in our biomarkers, including better differentiation between the subtypes of IBD. We will also discuss new targets and strategies in biomarker development, including combining modalities to create biomarker signatures to improve the ability to predict disease courses and response to therapy among individual patients.

show abstract

“…Fecal S100A12 is significantly increased in severe acute pediatric UC patients and decreases gradually when children are under clinical remission, but does not correlate with the therapeutic response (45). A recent study showed that the fecal S100A12 level is a reliable tool associated with the response to anti-TNF therapy of IBD (46). In addition to IBD, however, S100A12 is also increased in other inflammatory diseases, such as arthritis and Kawasaki disease (47, 48) (Table 1).…”

Section: I- Currently Available Biomarkersmentioning

confidence: 99%

Biomarkers of Inflammatory Bowel Disease

Viennois

Zhao

Merlin

2015

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

Diagnostics of inflammatory bowel diseases (IBDs) currently relies on a combination of biological and morphological tests. The current method of diagnostic remains a critical challenge for physicians in part due to their invasiveness and also for their limitations in term of diagnosis, prognosis, disease activity and severity assessment and therapeutic outcomes. Laboratory biomarkers can be used in the diagnosis and management of IBD but none of them has been proven to be ideal. Increasing efforts are being made to discover new biomarkers that can discriminate between the types of IBD, predict future responses to treatment, and aid in differential diagnosis, treatment planning and prognosis prediction. This review addresses the potential for current biomarkers and the emergence of the concept of biomarker signatures in IBD diagnostic and personalized medicine.

show abstract

Accuracies of Serum and Fecal S100 Proteins (Calprotectin and Calgranulin C) to Predict the Response to TNF Antagonists in Patients with Crohnʼs Disease

Abstract: Serum S100A12 level and fCal are reliable markers associated with response to induction therapy with anti-TNF. Fecal calprotectin was the best for predicting clinical remission in CD under maintenance therapy.

Cited by 75 publications

References 19 publications

Clinical improvement and reduction in serum calprotectin levels after an intensive exercise programme for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis

Clinical improvement and reduction in serum calprotectin levels after an intensive exercise programme for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis

New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes

Biomarkers of Inflammatory Bowel Disease

Contact Info

Product

Resources

About